BioAmber Inc. today announced that Robert Frost is joining its board of directors, effective today.
Mr. Frost will fill one of the board seats vacated by the resignations of Jean-Francois Huc and George F.J. Gosbee effective May 12, 2017 and May 11, 2017, respectively. Mr. Frost is a Partner at Naxos Capital Partners, one of the Company’s largest stockholders. Mr. Frost brings extensive financial experience and deep knowledge of the Company, its business and its industry. Mr. Frost has been elected a Class II director, to hold office until the 2018 annual meeting of stockholders. Please refer to the Company’s recently filed Current Report on Form 8-K for additional information related to the changes to the Company’s board of directors.
The Company is also pleased to announce the appointment of Mario Settino as the Company’s Chief Financial Officer. Mr. Settino replaces the Company’s current Interim Chief Financial Officer, Raymond Land, who will continue to serve as Chairman of the Company’s Board of Directors. Mr. Settino is seasoned professional with over 30 years of financial and operational experience in various industries such as services, manufacturing and high-end technology. He previously served as President and Chief Financial Officer of Peds Legwear and prior to this was Chief Financial Officer of Miranda Technologies. Mr. Settino has previously held senior financial positions with Loblaws, Bombardier and LGS, (an IBM company). He is a chartered professional accountant who began his career at Deloitte.
Finally, the Company is also pleased to announce that at the Company’s Annual Meeting of Stockholders held in Montreal, Canada on May 11, 2017, the Company’s stockholders voted to re-elect Kurt Briner and Ellen B. Richstone to the Company’s board of directors and to ratify the appointment of Deloitte LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2017.
Source: Street Insider
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”